Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$10.57 USD
+0.45 (4.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $10.53 -0.04 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.57 USD
+0.45 (4.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $10.53 -0.04 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Inovio Pharmaceuticals (INO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Inovio Pharmaceuticals (INO) closed the most recent trading day at $13.84, moving -0.93% from the previous trading session.
Company News for Dec 28, 2020
by Zacks Equity Research
Companies In The News Are: BUD, APO, INO, GOOGL, INTC, CLDR
6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19
by Zacks Equity Research
We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.
Are Options Traders Betting on a Big Move in Inovio Pharmaceuticals (INO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Inovio Pharmaceuticals (INO) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts
by Indrajit Bandyopadhyay
In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain from their vaccine development efforts.
Is the Options Market Predicting a Spike in Inovio (INO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
Here's Why Small-Cap ETFs Are Hitting New Highs
by Sweta Killa
Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.
Why Inovio Pharmaceuticals Skyrocketed on Tuesday
by Madeleine Johnson
Shares of coronavirus stock Inovio Pharmaceuticals (INO) surged again on Tuesday. INO was up about 18% in late-morning trading and ended the trading day up 20.4% to $13.63.
Company News for Sep 10, 2020
by Zacks Equity Research
Companies in the news are: SCWX, ITCI, AMYT, INO
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
by Sweta Killa
While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.
5 Growth ETFs & Stocks to Ride the Market Rally
by Sweta Killa
Growth investing has taken the lead over value and is likely to stay given a slew of reasons.
Why Inovio Pharmaceuticals Plunged 20% Today
by Madeleine Johnson
Shares of biotech company Inovio Pharmaceuticals (INO) fell sharply on Tuesday after announcing updates to its Covid-19 vaccine candidate, INO-4800.
Moderna Collaborates With Catalent for Coronavirus Vaccine
by Zacks Equity Research
Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.
Futures Reverse Higher Overnight
by Jeremy Mullin
Negative headlines can???t shake the bulls
Novavax (NVAX) Up More Than 1200% Year to Date: Here's Why
by Zacks Equity Research
Novavax's (NVAX) coronavirus vaccine candidate NVX-CoV2373 enters clinical studies. The company also plans to file a BLA on its influenza vaccine candidate, NanoFlu.
5 High Beta ETFs That Are in High Momentum
by Sanghamitra Saha
Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta ETFs that are in high momentum should gain ahead.
Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Here's How Americans Are Regaining Confidence: 5 Picks
by Sanghamitra Saha
U.S. consumer confidence gained in May and beat the expectations of economists polled by Dow Jones.
Tap the Solid Momentum in These 5 Solid High-Beta Stocks
by Sanghamitra Saha
Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta stocks that are in high momentum should gain ahead.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.
Regeneron's BLA for Ebola Vaccine Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts Regeneron's (REGN) BLA for REGN-EB3 under a priority review to treat the deadly Ebola virus infection. A verdict is pending on Oct 25, 2020.
Biotech Stocks Accelerate Efforts for Coronavirus Treatments
by Zacks Equity Research
Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals